Helius Medical Plunges 45.77% Despite Reimbursement Wins

On June 12, 2025, Helius Medical's stock experienced a significant drop of 45.77% in pre-market trading, marking a substantial decline in its share price.

Helius Medical Technologies, Inc. has recently made strides in securing reimbursement for its Portable Neuromodulation Stimulator (PoNS®) Device. Aetna has authorized payment for the PoNS Device at an out-of-network negotiated price of $18,350, following similar approvals from Anthem and United Healthcare. This development is crucial as it expands the device's accessibility and reimbursement options, potentially boosting its market penetration.

Additionally, Helius Medical has been actively engaged in clinical studies and regulatory compliance. The company announced the completion of site participation enrollment for its U.S. registrational program in stroke, which includes top neurorehabilitation centers. This move is expected to enhance the credibility and reach of the PoNS Therapy, further solidifying its position in the market.

Helius Medical's efforts to achieve fair market access for its PoNS Device have also been noteworthy. The company has been working on reimbursement payment determinations from CMS, which could impact the device's affordability and accessibility for patients. These initiatives are part of Helius Medical's broader strategy to ensure that its innovative technology reaches a wider audience.